su011248
AIDS-related Lymphoblastic Lymphoma
National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the AIDS-related Lymphoblastic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Procarbazine AIDS Malignancy Consortium | Phase 2 | B |
ETOPOSIDE AIDS Malignancy Consortium | Phase 2 | B |
Inno-206 AIDS Malignancy Consortium | Phase 2 | B |
Cyclophosphamide AIDS Malignancy Consortium | Phase 2 | B |
PREDNISONE TABLETS AIDS Malignancy Consortium | Phase 2 | B |
View all 21 →
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →